Gary Thomas, MD
Internal Medicine · Winfield, ALNPI 1407895261
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $885 and has fallen 53.5% since, to $412 in 2025.
Across 208 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$551
- Novo Nordisk$463
- Johnson & Johnson$391
- EMD Serono, Inc.$331
- AstraZeneca$306
- Lilly USA, LLC$262
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,577100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $551 |
| Novo Nordisk | 32 | $463 |
| Johnson & Johnson | 24 | $391 |
| EMD Serono, Inc. | 18 | $331 |
| AstraZeneca | 17 | $306 |
| Lilly USA, LLC | 15 | $262 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $153 |
| Pfizer | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 6 | $150 |
| Mylan Specialty L.p. | 7 | $136 |
| Boehringer Ingelheim | 5 | $78 |
| Atland Pharmaceuticals, LLC | 1 | $76 |
| Dexcom, Inc. | 3 | $67 |
| Neurocrine Biosciences, Inc. | 3 | $64 |
| Lundbeck LLC | 3 | $62 |
| GSK | 3 | $57 |
| Novartis | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Exact Sciences | 1 | $19 |
| Bayer | 1 | $17 |
| Abbott | 1 | $16 |
| Merck | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$3,592 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $181,365 |
| OzempicSemaglutide | 147 | $158,093 |
| MounjaroTirzepatide | 98 | $105,860 |
| FarxigaDapagliflozin Propanediol | 116 | $82,298 |
| JardianceEmpagliflozin | 68 | $43,393 |
| JanuviaSitagliptin Phosphate | 53 | $32,016 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $29,041 |
| InvokanaCanagliflozin | 38 | $27,435 |
| XareltoRivaroxaban | 35 | $26,979 |
| RybelsusSemaglutide | 23 | $25,929 |
| TrulicityDulaglutide | 19 | $24,509 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $19,380 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,524 |
| Praluent PenAlirocumab | 19 | $12,155 |
| Atorvastatin Calcium | 605 | $9,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $463 | $184,023170 claims |
| PfizerEliquis | $151 | $181,365332 claims |
| Lilly USA, LLCMounjaro, Trulicity | $262 | $130,369117 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $306 | $95,608142 claims |
| Johnson & JohnsonInvokana, Xarelto | $391 | $54,41373 claims |
| Boehringer IngelheimJardiance | $78 | $43,39368 claims |
| MerckJanuvia | $14 | $32,01653 claims |
| GSKBreo Ellipta, Anoro Ellipta | $57 | $21,98841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Winfield
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.